Progressing bevacizumab-induced diffusion restriction is associated with coagulative necrosis surrounded by viable tumor and decreased overall survival in patients …
HS Nguyen, N Milbach, SL Hurrell… - American Journal …, 2016 - Am Soc Neuroradiology
BACKGROUND AND PURPOSE: Patients with recurrent glioblastoma often exhibit regions
of diffusion restriction following the initiation of bevacizumab therapy. Studies suggest that …
of diffusion restriction following the initiation of bevacizumab therapy. Studies suggest that …
Diagnostic accuracy of centrally restricted diffusion in the differentiation of treatment-related necrosis from tumor recurrence in high-grade gliomas
N Zakhari, MS Taccone, C Torres… - American Journal …, 2018 - Am Soc Neuroradiology
BACKGROUND AND PURPOSE: Centrally restricted diffusion has been demonstrated in
recurrent high-grade gliomas treated with bevacizumab. Our purpose was to assess the …
recurrent high-grade gliomas treated with bevacizumab. Our purpose was to assess the …
Persistent diffusion-restricted lesions in bevacizumab-treated malignant gliomas are associated with improved survival compared with matched controls
S Mong, BM Ellingson, PL Nghiemphu… - American journal …, 2012 - Am Soc Neuroradiology
BACKGROUND AND PURPOSE: A subset of patients with malignant glioma develops
conspicuous lesions characterized by persistent restricted diffusion during treatment with …
conspicuous lesions characterized by persistent restricted diffusion during treatment with …
[CITATION][C] Diffusion magnetic resonance imaging detects pathologically confirmed, nonenhancing tumor progression in a patient with recurrent glioblastoma …
ER Gerstner, MP Frosch, TT Batchelor - Journal of clinical oncology …, 2009 - europepmc.org
Diffusion magnetic resonance imaging detects pathologically confirmed, nonenhancing tumor
progression in a patient with recurrent glioblastoma receiving bevacizumab. - Abstract …
progression in a patient with recurrent glioblastoma receiving bevacizumab. - Abstract …
Bevacizumab-induced diffusion-restricted lesions in malignant glioma patients
J Rieger, O Bähr, K Müller, K Franz, J Steinbach… - Journal of neuro …, 2010 - Springer
Bevacizumab is an anti-vascular endothelial growth factor (VEGF) antibody with activity
against recurrent malignant glioma inducing high rates of objective responses as assessed …
against recurrent malignant glioma inducing high rates of objective responses as assessed …
[HTML][HTML] Restriction-spectrum imaging of bevacizumab-related necrosis in a patient with GBM
N Farid, DB Almeida-Freitas, NS White… - Frontiers in …, 2013 - frontiersin.org
Importance: With the increasing use of antiangiogenic agents in the treatment of high-grade
gliomas, we are becoming increasingly aware of distinctive imaging findings seen in a …
gliomas, we are becoming increasingly aware of distinctive imaging findings seen in a …
Isolated diffusion restriction precedes the development of enhancing tumor in a subset of patients with glioblastoma
A Gupta, RJ Young, S Karimi, S Sood… - American journal …, 2011 - Am Soc Neuroradiology
BACKGROUND AND PURPOSE: Most response criteria for patients with glioblastoma rely
on increases in the contrast enhancing abnormality to determine tumor progression. Our aim …
on increases in the contrast enhancing abnormality to determine tumor progression. Our aim …
Sustained focal antitumor activity of bevacizumab in recurrent glioblastoma
O Bähr, PN Harter, LM Weise, SJ You, M Mittelbronn… - Neurology, 2014 - AAN Enterprises
Objectives: To investigate the relevance of bevacizumab (BEV)-induced diffusion-restricted
lesions and T1-hyperintense lesions in patients with recurrent glioblastoma. Methods: We …
lesions and T1-hyperintense lesions in patients with recurrent glioblastoma. Methods: We …
Histogram analysis of apparent diffusion coefficient within enhancing and nonenhancing tumor volumes in recurrent glioblastoma patients treated with bevacizumab
While patients with recurrent glioblastoma receiving anti-angiogenic therapy demonstrate
significant response rates, the benefit on patient survival is less clear. We assessed whether …
significant response rates, the benefit on patient survival is less clear. We assessed whether …
Bevacizumab-induced diffusion restriction in patients with glioma: tumor progression or surrogate marker of hypoxia?
J Rieger, O Bähr, MW Ronellenfitsch… - Journal of Clinical …, 2010 - ascopubs.org
TO THE EDITOR: Therapy with bevacizumab results in high response rates in patients with
malignant glioma. 1 However, the mechanisms of action of bevacizumab are poorly …
malignant glioma. 1 However, the mechanisms of action of bevacizumab are poorly …
Related searches
- diffusion restriction overall survival
- diffusion restriction recurrent glioblastoma
- overall survival recurrent glioblastoma
- diffusion restriction coagulative necrosis
- diffusion restriction viable tumor
- overall survival coagulative necrosis
- coagulative necrosis recurrent glioblastoma
- viable tumor recurrent glioblastoma
- overall survival viable tumor
- coagulative necrosis viable tumor
- diffusion restriction patients with glioma
- diffusion restriction surrogate marker
- poor survival glioblastoma patients
- diffusion coefficient glioblastoma patients
- histogram analysis glioblastoma patients
- tumor progression patients with glioma